Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Dr. Yvonne L Greenstreet$30.1B
Market Cap • 25/07/20242003
(há 21 anos)
2004
(20 years ago)
NASDAQ
Listagem
Cambridge
Sede • Massachusetts2.002
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
ALNYSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.